Option chain shows key data for Coya Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Coya Therapeutics.

Coya Therapeutics (NASDAQ:COYA) Stock, Option Chain

COYA THERAPEUTICS INC

Coya Therapeutics

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Meta Platforms Inc. (META)

News

Pre-Market Outlook

Markets

Trading Ideas

ANET

BTMD

CFLT

COYA

ETWO

LGMK

MSFT

NAOV

PAPL

PBPB

QCOM

RSVR

SGHC

SNDR

TRNR

VSTS

ZYBT

Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

Movers

General

Coya Therapeutics&#39; Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer&#39;s patients, with no serious adverse events.

Coya Therapeutics&#39; Alzheimer&#39;s Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Market-Moving Exclusives

Exclusives

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

Coya Therapeutics Inc

Press Releases

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Management

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

AVIR

REPL

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Atossa Therapeutics

C4 Therapeutics

Coherus Oncology

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

Entera Bio

EXoZymes

Forte Biosciences

Genelux

HilleVax

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Invivyd

Macrogenics

OKYO Pharma

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Surrozen

TScan Therapeutics

Tenaya Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Chardan Capital

D. Boral Capital

Rodman & Renshaw

EF Hutton

Comments

Coya Therapeutics

Coya Therapeutics (COYA) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell